BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35788718)

  • 21. LncRNA ADPGK-AS1 promotes pancreatic cancer progression through activating ZEB1-mediated epithelial-mesenchymal transition.
    Song S; Yu W; Lin S; Zhang M; Wang T; Guo S; Wang H
    Cancer Biol Ther; 2018 Jul; 19(7):573-583. PubMed ID: 29667486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNF185 antisense RNA 1 (RNF185-AS1) promotes proliferation, migration, and invasion in papillary thyroid carcinoma.
    Liu D; Zhang M; Song Y; Yang N
    Anticancer Drugs; 2022 Jul; 33(6):595-606. PubMed ID: 35324519
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNF185-AS1 promotes hepatocellular carcinoma progression through targeting miR-221-5p/integrin β5 axis.
    Huang C; Li K; Huang R; Zhu J; Yang J
    Life Sci; 2021 Feb; 267():118928. PubMed ID: 33358902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA SOX21-AS1 promotes cell proliferation and invasion through upregulating PAK7 expression by sponging miR-144-3p in glioma cells.
    Gai SY; Yuan ZH
    Neoplasma; 2020 Mar; 67(2):333-343. PubMed ID: 31973536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long non-coding RNA ASB16-AS1 enhances cell proliferation, migration and invasion via functioning as a ceRNA through miR-1305/Wnt/β-catenin axis in cervical cancer.
    Liu W; Zhuang R; Feng S; Bai X; Jia Z; Kapora E; Tan W
    Biomed Pharmacother; 2020 May; 125():109965. PubMed ID: 32058219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KDM4A-AS1 Promotes Cell Proliferation, Migration, and Invasion via the miR-4306/STX6 Axis in Hepatocellular Carcinoma.
    Cao W; Ren Y; Liu Y; Cao G; Chen Z; Wang F
    Crit Rev Eukaryot Gene Expr; 2024; 34(4):55-68. PubMed ID: 38505873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long non-coding RNA DHRS4 antisense RNA 1 inhibits ectopic endometrial cell proliferation, migration, and invasion in endometriosis by regulating microRNA-139-5p expression.
    Cui X; Zhou S; Lin Y
    Bioengineered; 2022 Apr; 13(4):9792-9804. PubMed ID: 35414313
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LncRNA RPL34-AS1 suppresses the proliferation, migration and invasion of esophageal squamous cell carcinoma via targeting miR-575/ACAA2 axis.
    Zhang H; Pan E; Zhang Y; Zhao C; Liu Q; Pu Y; Yin L
    BMC Cancer; 2022 Sep; 22(1):1017. PubMed ID: 36162992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA FOXD3-AS1 promotes proliferation, invasion and migration of cutaneous malignant melanoma via regulating miR-325/MAP3K2.
    Chen X; Gao J; Yu Y; Zhao Z; Pan Y
    Biomed Pharmacother; 2019 Dec; 120():109438. PubMed ID: 31541886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway.
    Li C; Feng S; Chen L
    Mol Cell Biochem; 2021 Feb; 476(2):699-713. PubMed ID: 33106913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
    Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
    Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the long non-coding RNA UNC5B-AS1/miR-4455/RSPO4 axis reduces cervical cancer growth in vitro and in vivo.
    Fu J; Zhang Y; Wang M; Hu J; Fang Y
    J Gene Med; 2021 Dec; 23(12):e3382. PubMed ID: 34350661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upregulated lncRNA Cyclin-dependent kinase inhibitor 2B antisense RNA 1 induces the proliferation and migration of colorectal cancer by miR-378b/CAPRIN2 axis.
    Zheng Y; Zeng J; Xia H; Wang X; Chen H; Huang L; Zeng C
    Bioengineered; 2021 Dec; 12(1):5476-5490. PubMed ID: 34511033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis.
    Kan L; Yang M; Zhang H
    Biol Direct; 2023 Jul; 18(1):36. PubMed ID: 37403106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LncRNA MCM3AP-AS1 promotes proliferation, migration and invasion of oral squamous cell carcinoma cells via regulating miR-204-5p/FOXC1.
    Li H; Jiang J
    J Investig Med; 2020 Oct; 68(7):1282-1288. PubMed ID: 32690597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA NR2F1-AS1 is involved in the progression of endometrial cancer by sponging miR-363 to target SOX4.
    Wang L; Zhao S; Mingxin YU
    Pharmazie; 2019 May; 74(5):295-300. PubMed ID: 31109400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 38. Long Noncoding RNA HOXB-AS1 Is Upregulated in Endometrial Carcinoma and Sponged miR-149-3p to Upregulate Wnt10b.
    Liu D; Qiu M; Jiang L; Liu K
    Technol Cancer Res Treat; 2020; 19():1533033820967462. PubMed ID: 33073693
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LncRNA CDKN2B-AS1/miR-141/cyclin D network regulates tumor progression and metastasis of renal cell carcinoma.
    Dasgupta P; Kulkarni P; Majid S; Hashimoto Y; Shiina M; Shahryari V; Bhat NS; Tabatabai L; Yamamura S; Saini S; Tanaka Y; Dahiya R
    Cell Death Dis; 2020 Aug; 11(8):660. PubMed ID: 32814766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LncRNA LOXL1-AS1 inhibited cell proliferation, migration and invasion as well as induced apoptosis in breast cancer via regulating miR-143-3p.
    Li GH; Yu JH; Yang B; Gong FC; Zhang KW
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10400-10409. PubMed ID: 31841194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.